Drug-drug interaction between pravastatin and gemfibrozil (antihyperlipidemic) with gliclazide (antidiabetic) in rats

Journal of Young Pharmacists

Volumn 2, Issue 2, 2010, Pages 152-155

  Sultanpur, C M ^a   Satyanarayana, S ^b   Reddy, N S ^a   Kumar, K E ^b   Kumar, S ^a  

^a Government College of Pharmacy   (India)

^b ANDHRA UNIVERSITY   (India)

Author keywords

Diabetes; drug drug gliclazide; gemfibrozil; interaction; pharmacodynamics; pravastatin

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GEMFIBROZIL; GLICLAZIDE; GLUCOSE; PRAVASTATIN;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 78049375226     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.4103/0975-1483.63157     Document Type: Article

References (19)

1. Bak JF, Pedersen O. Gliclazide and insulin action in human muscle. Diabetes Res Clin Pract 1991;14:S61-4.
2. Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes 1998;47:1412-8.
3. Harrower AD. Comparative tolerability of sulfonylureas in diabetes mellitus. Drug Saf 2000;22:313-20.
4. Ziegler O, Drouin P. Hemobiological properties of gliclazide. J Diabetes Complications 1994;8:235-9.
5. Philipson LH, Steiner DF. Pas de deux or more: the sulfonylurea receptor and K+ channels. Science 1995;268:372-3.
6. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanism of pharmacokinetic events. Clin Pharmacokinet 2000;39:397-412.
7. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-15.
8. Wen X, Wang JS, Backman JT, Kivist KT, Neuvonen PJ. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001;29:1359-61.
9. Ferner RE, Chaplin S. The relationship between the pharmacokinetics and Pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet 1987;12:379-401.
10. Riley V. Adaptation of orbital bleeding technique to rapid serial blood studies. Proc Soc Exp Bio Med 1960; 104: 751-4.
11. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969;22:158-61.
12. Heikkila RE. The prevension of alloxan-induced diabetes in mice by dimethyl sulphoxide. Eur J Pharmacol 1977;44:191-3.
13. Miyazaki H, Fijii T, Yoshida K, Arakawa S, Furukawa H. Disposition and metabolism of [3 H]-gliclazide in rats. Eur J Drug Metab Pharmacokinet 1983;8:117-3.
14. Benakis A, Glasson B. Metabolic study of 14 C-labelled gliclazide in normal rats and in rats with streptozotocin-induced diabetes. Gliclazide and Treatment of Diabetes. In: Keen H, editor. London: Academic Press and the Royal Society of Medicine; 1980. p. 57-69.
15. Rollins DE, Klaassen CD. Biliary excretion of drugs in man. Clin Pharmacokinet 1979;4:368-79.
16. Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract 1991;14:S21-36.
17. Wajchenberg BL, Santomauro AT, Porrelli RN. Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Res Clin Pract 1993;20:147-54.
18. Hamberger C, Barre J, Zini R, Taiclet A, Houin G, Tillement JP. In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs. Int J Clin Pharmacol Res 1986;6:441-9.
19. Kobayashi K, Kimura M, Sakoguchi T, Kitani Y, Hata M, Matsuoka A. Influence of blood proteins on biomedical analysis III. Pharmacokinetics and protein binding of gliclazide. J Pharmacobiodyn 1981;4:436-42.